SEC Form 4 · accession 0001213900-18-004593
DelMar Pharmaceuticals, Inc. · DMPI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Hoffman
Director
Period of report
Apr 13, 2018
Accepted (ET)
Apr 17, 2018 · 4:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001498382
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options (Right to Buy)F1 | $1.06 | Apr 13, 2018 | A | 36,000 | A | Mar 31, 2021 | Apr 13, 2028 | Common Stock | 36,000 | 36,000 | D |
| Performance Stock UnitsF2 | — | Apr 13, 2018 | A | 200,000 | A | — | Jul 7, 2022 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F112,000 options vest on March 31, 2019, and 3,000 options vest each three months thereafter starting June 30, 2019.
- F2Each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on achievement of specified targets related to the Company's financial performance.